INNOVADERM CRO IS NOW INDERO.
READ THE ANNOUNCEMENT
Talk to us
circle

A Maximum-Use Trial of Ruxolitinib Cream in Children Aged 2-11 Years with Moderate to Severe Atopic Dermatitis

Multiple Authors

Multiple Authors

2024-11-17

SHARE THIS POST

Date: 2024-11-17

Authors: Linda Stein Gold, Robert Bissonnette, Seth Forman, Andrea Zaenglein, YuTzu Kuo, Brett Angel, Xuejun Chen, Howard Kallender, Amy S Paller

Category: Dermatitis (all types), Eczema

Background: Ruxolitinib cream has demonstrated anti-inflammatory and antipruritic activity and was well tolerated in a phase 3 study in patients aged 2-11 years with mild to moderate atopic dermatitis (AD).

Objective: This study examined the safety, tolerability, pharmacokinetics, efficacy, and quality of life (QoL) with ruxolitinib cream under maximum-use conditions and with longer-term use.

Read more on pubmed
SHARE THIS POST

Subscribe to our newsletter.

Do not miss out on valuable insights and research updates. Join our scientific community today!

This field is for validation purposes and should be left unchanged.

3530 Saint-Laurent Boulevard
Suite 300

Montreal, QC, H2X 2V1, Canada

Operational Capabilities
  • North America
  • Europe
  • Asia Pacific
  • Latin America
EXPERTISE
OTHER THERAPEUTIC AREAS
STAGES
CRO SERVICES
About
Youtube X-twitter Linkedin

© 2025 Indero. All Rights Reserved. Privacy Policy. Designed and developed by Altitude Marketing.

logo mobile
Talk to us

Is Now

We are excited to announce that Innovaderm is rebranding our CRO division as Indero (in-dAIR-oh). This rebranding reflects our ongoing commitment to innovation and our expansion into the field of rheumatology, a therapeutic area closely linked to dermatology. As a dual-focus CRO specializing in both dermatology and rheumatology, this strategic decision marks a significant milestone for our organization, and we are eager to embark on this new chapter with our valued partners and clients. Additionally, our Clinical Research Unit (CRU) will keep the name Innovaderm and will continue to conduct dermatology studies.

Site Selection & Management

Our long-standing relationships with key opinion leaders and highly performing sites, result in optimized start-up processes that deliver strong results in the least amount of time. As part of our site evaluation, our team utilizes past performance metrics, recruitment projections based on competitive landscape, and detailed feasibility surveys to determine a site’s capabilities and interest in a study.

SEE SERVICES
Hands, tablet and contact us with healthcare marketing or advertising on a website in the medical industry.

Patient Recruitment

Our dedicated patient recruitment and advertising team integrates with the study team to tailor recruitment strategies, customize central ad campaigns, develop advertising creative, and continuously track and adapt recruitment goals. Our patient-centric approach is enhanced by Clinago, our technology enabled recruitment service.

SEE SERVICES

PROJECT MANAGEMENT

We orchestrate all study activities and deliverables, including site selection process, budget and contract negotiations, and patient engagement, recruitment enrollment projections, all while respecting your study timelines.

SEE SERVICES
PROJECT MANAGEMENT

We orchestrate all study activities and deliverables, including site selection process, budget and contract negotiations, and patient engagement, recruitment enrollment projections, all while respecting your study timelines.

SEE SERVICES